171 related articles for article (PubMed ID: 38102338)
21. Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy.
Yu C; Zhang M; Song J; Zheng X; Xu G; Bao Y; Lan J; Luo D; Hu J; Li JJ; Shi H
Mol Biomed; 2020 Nov; 1(1):12. PubMed ID: 35006410
[TBL] [Abstract][Full Text] [Related]
22. Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth.
Uka R; Britschgi C; Krättli A; Matter C; Mihic D; Okoniewski MJ; Gualandi M; Stupp R; Cinelli P; Dummer R; Levesque MP; Shakhova O
Oncogene; 2020 May; 39(20):4132-4154. PubMed ID: 32238882
[TBL] [Abstract][Full Text] [Related]
23. DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype.
Sanna A; Phung B; Mitra S; Lauss M; Choi J; Zhang T; Njauw CN; Cordero E; Harbst K; Rosengren F; Cabrita R; Johansson I; Isaksson K; Ingvar C; Carneiro A; Brown K; Tsao H; Andersson M; Pietras K; Jönsson G
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040798
[TBL] [Abstract][Full Text] [Related]
24. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
25. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
26. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
27. Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V; Eichhoff O; Gerner C; Paulitschke P; Bileck A; Mohr T; Cheng PF; Leitner A; Guenova E; Saulite I; Freiberger SN; Irmisch A; Knapp B; Zila N; Chatziisaak TP; Stephan J; Mangana J; Kunstfeld R; Pehamberger H; Aebersold R; Dummer R; Levesque MP
EMBO J; 2019 Aug; 38(15):e95874. PubMed ID: 31267558
[TBL] [Abstract][Full Text] [Related]
28. TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
Yin M; Soikkeli J; Jahkola T; Virolainen S; Saksela O; Hölttä E
Am J Pathol; 2012 Dec; 181(6):2202-16. PubMed ID: 23063511
[TBL] [Abstract][Full Text] [Related]
29. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.
Seong I; Min HJ; Lee JH; Yeo CY; Kang DM; Oh ES; Hwang ES; Kim J
PLoS One; 2012; 7(2):e31477. PubMed ID: 22363655
[TBL] [Abstract][Full Text] [Related]
30. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.
Gutierrez-Prat N; Zuberer HL; Mangano L; Karimaddini Z; Wolf L; Tyanova S; Wellinger LC; Marbach D; Griesser V; Pettazzoni P; Bischoff JR; Rohle D; Palladino C; Vivanco I
Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35580987
[TBL] [Abstract][Full Text] [Related]
31. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals.
Jung SN; Lim HS; Liu L; Chang JW; Lim YC; Rha KS; Koo BS
Sci Rep; 2018 Feb; 8(1):2718. PubMed ID: 29426928
[TBL] [Abstract][Full Text] [Related]
32. Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.
Makino E; Gutmann V; Kosnopfel C; Niessner H; Forschner A; Garbe C; Sinnberg T; Schittek B
Cell Death Dis; 2018 Sep; 9(9):930. PubMed ID: 30206212
[TBL] [Abstract][Full Text] [Related]
33. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
34. Identification and functional analysis of SOX10 phosphorylation sites in melanoma.
Cronin JC; Loftus SK; Baxter LL; Swatkoski S; Gucek M; Pavan WJ
PLoS One; 2018; 13(1):e0190834. PubMed ID: 29315345
[TBL] [Abstract][Full Text] [Related]
35. Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7α modulates melanoma cell migration.
Lv XB; Wu W; Tang X; Wu Y; Zhu Y; Liu Y; Cui X; Chu J; Hu P; Li J; Guo Q; Cai Z; Wu J; Hu K; Ouyang N
Oncotarget; 2015 Nov; 6(34):36370-82. PubMed ID: 26461473
[TBL] [Abstract][Full Text] [Related]
36. TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination.
Cantelli G; Orgaz JL; Rodriguez-Hernandez I; Karagiannis P; Maiques O; Matias-Guiu X; Nestle FO; Marti RM; Karagiannis SN; Sanz-Moreno V
Curr Biol; 2015 Nov; 25(22):2899-914. PubMed ID: 26526369
[TBL] [Abstract][Full Text] [Related]
37. Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses.
Abou-Hamad J; Hodgins JJ; Yakubovich E; Vanderhyden BC; Ardolino M; Sabourin LA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201278
[TBL] [Abstract][Full Text] [Related]
38. SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway.
Tong X; Li L; Li X; Heng L; Zhong L; Su X; Rong R; Hu S; Liu W; Jia B; Liu X; Kou G; Han J; Guo S; Hu Y; Li C; Tao Q; Guo Y
Oncotarget; 2014 Nov; 5(21):10571-83. PubMed ID: 25301735
[TBL] [Abstract][Full Text] [Related]
39. Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.
Wattson DA; Sullivan RJ; Niemierko A; Merritt RM; Lawrence DP; Oh KS; Flaherty KT; Shih HA
J Neurooncol; 2015 May; 123(1):75-84. PubMed ID: 25864098
[TBL] [Abstract][Full Text] [Related]
40. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Haist M; Stege H; Kuske M; Bauer J; Klumpp A; Grabbe S; Bros M
Cancer Metastasis Rev; 2023 Jun; 42(2):481-505. PubMed ID: 37022618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
